MASLD – Medxy AI

Intermittent Calorie Restriction: A Promising Dietary Strategy for Metabolic Dysfunction-Associated Steatotic Liver Disease

By MedXY 08/08/2025

Recent trials show intermittent calorie restriction (ICR) significantly reduces liver fat content in MASLD and NAFLD, especially in obese patients, offering an effective and well-tolerated alternative to conventional diets.

Clinical Updates Wellness & Lifestyle

Empowering Community Liver Health: Insights from the LOCATE-NAFLD Trial on Nurse-Led MASLD Screening

By MedXY 08/08/2025

The LOCATE-NAFLD trial demonstrates that nurse-delivered, community-based liver screening is highly acceptable and effective for identifying high-risk MASLD patients, but faces challenges in sustainable adoption.

Clinical Updates Wellness & Lifestyle

Mediterranean Diet Combined with Early Time-Restricted Feeding: A Promising Strategy for MASLD – Insights from the CHRONO-NAFLD Trial

By MedXY 08/08/2025

A 12-week hypocaloric Mediterranean diet with early time-restricted feeding improved glycaemic control and cardiometabolic risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) compared to unrestricted timing or late time-restricted feeding.

Clinical Updates Wellness & Lifestyle

Consecutive Fecal Microbiota Transplantation in MASLD: Insights from a Double-Blind Randomized Controlled Trial

By MedXY 08/07/2025

A double-blind RCT found that three consecutive fecal microbiota transplantations did not significantly improve hepatic steatosis or metabolic parameters in patients with MASLD, suggesting patient selection based on microbiota diversity may be crucial.

Medical News Wellness & Lifestyle

Waist Size Proves Key to Assessing Liver Health

By MedXY 08/06/2025

Waist circumference is a superior predictor of metabolic liver diseases, outperforming BMI and other body metrics in assessing MASLD, MASH, and liver stiffness risks.

Clinical Updates Wellness & Lifestyle

Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction

By MedXY 08/02/2025

Retatrutide, a triple hormone receptor agonist, significantly reduces body fat and liver fat in patients with type 2 diabetes and MASLD, with a favorable safety profile and preservation of lean mass.

Clinical Updates Wellness & Lifestyle

Two-Step Clinical Pathway for MASLD: Precision Risk Stratification of Hepatic Events Validated in a Multinational Prospective Cohort

By MedXY 08/01/2025

A large, multinational cohort study demonstrates that a two-step algorithm—combining FIB-4 with VCTE—precisely stratifies MASLD patients by liver-related event risk, optimizing resource use and guiding clinical management.

Clinical Updates Wellness & Lifestyle

Weekend Warrior Exercise Patterns: Comparable Cardiometabolic Protection to Regular Activity in Diabetes and MASLD

By MedXY 07/31/2025

Accumulating 150 minutes of moderate-to-vigorous physical activity weekly, either as a 'weekend warrior' or in regular sessions, significantly reduces mortality and cardiometabolic risk in adults with diabetes and MASLD.

Medical News Wellness & Lifestyle

Obesity-Linked Liver Cancer: A Preventable Crisis on the Rise

By MedXY 07/31/2025

Over 60% of liver cancer cases are preventable, yet rising obesity and metabolic dysfunction threaten progress. The Lancet Commission outlines urgent strategies to curb a projected doubling of global liver cancer burden by 2050.